Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
The PBM's (Prescription Benefit Managers) practices are increasing healthcare costs to the patient and the payers (commercial and government). The discounts received due to their volume are being shared partially with the payers with the highest percent going to their bottom line. Additionally, DIR fees from pharmacy's are not being shared with patients or payors thus driving up costs and increasing PBM profits in a less than transparent way. Why should any industry have a safe harbor for kickbacks? At a time when drug prices are soaring, and the public is at risk of harm from shortages of critical medications and sterile products, the FTC MUST investigate how the middlemen of GPO and PBM are causing these issues.